These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A double-blind comparison of the acridane derivative, clomacran phosphate and trifluoperazine in schizophrenia. Angus JW; Deutsch LJ; Edwards JG; Simpson GM Behav Neuropsychiatry; 1969 Apr; 1(1):13-8. PubMed ID: 4920977 [No Abstract] [Full Text] [Related]
7. Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid. Dobryszycka W; Osada J; Gerber J; Jablonski K Arch Immunol Ther Exp (Warsz); 1973; 21(2):271-9. PubMed ID: 4790848 [No Abstract] [Full Text] [Related]
8. [C-283 in treatment of peritoneal and pleural effusions in patients with ovarian carcinoma]. Kwaśniewska-Rokicińska Pol Tyg Lek; 1971 Mar; 26(10):361-3. PubMed ID: 5102483 [No Abstract] [Full Text] [Related]
10. [Early changes in lung tissue following isolation perfusion with a cytostatic of Polish production C-283]. Gacyk W Pol Przegl Chir; 1974 Jun; 46(6):715-22. PubMed ID: 4840924 [No Abstract] [Full Text] [Related]
11. Preclinical pharmacologic studies on 1-nitro-9-(dimethylaminopropylamino)-acridine and its n-oxide. II. Chronic action. Gieldanowski J; Patkowski J; Szaga B; Teodorczyk J Arch Immunol Ther Exp (Warsz); 1972; 20(3):419-44. PubMed ID: 5055688 [No Abstract] [Full Text] [Related]
13. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415 [TBL] [Abstract][Full Text] [Related]
14. [Isophosphamide: study of its toxicity and immediate results with large doses]. Araujo CE; Tagle JC Prensa Med Argent; 1971 Dec; 58(40):1953-8. PubMed ID: 5137763 [No Abstract] [Full Text] [Related]
15. One-year trial of the antipsychotic acridan compound, SK AND F 14336. Bishop MP; Mason LB; Gallant DM Behav Neuropsychiatry; 1969 Jun; 1(3):4-9. PubMed ID: 5398104 [No Abstract] [Full Text] [Related]
16. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Plaxe SC; Blessing JA; Bookman MA; Creasman WT Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972 [TBL] [Abstract][Full Text] [Related]